First Choice Healthcare Solutions (FCHS) 10-Q/A 15 Nov 13 2013 Q3 Quarterly report (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 14, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'First Choice Healthcare Solutions, Inc.	'
Entity Central Index Key	'0001416876	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'FCHS	'
Entity Common Stock, Shares Outstanding	'	14,701,450
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
ASSETS	'	'
Cash	$197,020	$67,045
Cash-restricted	258,311	221,148
Accounts receivable	1,174,488	527,867
Employee loans	35,000	0
Prepaid and other current assets	118,226	69,970
Capitalized financing costs, current portion	57,348	57,348
Total current assets	1,840,393	943,378
Property, plant and equipment, net of accumulated depreciation of $1,834,133 and $1,465,939	8,708,199	8,756,631
Other assets	'	'
Capitalized financing costs, long term portion	152,226	152,911
Patient list, net of accumulated amortization of $30,000	270,000	275,609
Patents	286,500	0
Investments	450,000	0
Deposits	2,713	2,719
Total other assets	1,161,439	431,239
Total assets	11,710,031	10,131,248
LIABILITIES AND STOCKHOLDERS' DEFICIT	'	'
Accounts payable and accrued expenses	871,860	576,209
Line of credit, short term	635,000	0
Notes payable, current portion	738,349	690,586
Note payable, related party	300,000	300,000
Convertible note payable, net of unamortized debt discount of $106,744 and $160,543, respectively	58,098	43,537
Unearned revenue	40,760	39,438
Total current liabilities	2,644,067	1,649,770
Long term debt:	'	'
Deposits held	60,150	47,399
Revolving line of credit, related party	141,448	153,330
Line of credit, long term	502,196	0
Notes payable, long term portion	9,119,238	9,410,296
Derivative liability	210,961	171,987
Total long term debt	10,033,993	9,783,012
Total liabilities	12,678,060	11,432,782
Stockholders' deficit	'	'
Preferred stock, $0.01 par value; 1,000,000 shares authorized, Nil issued and outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 14,695,127 and 12,706,795 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively	14,695	12,707
Additional paid in capital	8,235,380	7,244,993
Common stock subscriptions	0	100,000
Accumulated deficit	-9,218,104	-8,659,234
Total stockholders' deficit	-968,029	-1,301,534
Total liabilities and stockholders' deficit	$11,710,031	$10,131,248

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accumulated depreciation of property plant and equipment (in dollars)	$1,834,133	$1,465,939
Accumulated amortization of Patient list (in dollars)	30,000	30,000
Debt instrument, unamortized discount (in dollars)	$106,744	$160,543
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	14,695,127	12,706,795
Common stock, shares outstanding	14,695,127	12,706,795

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
Net patient service revenue	$1,395,610	$798,077	$3,739,435	$1,707,694
Rental revenue	259,120	270,547	786,546	883,179
Total Revenue	1,654,730	1,068,624	4,525,981	2,590,873
Operating expenses:	'	'	'	'
Salaries and benefits	735,888	470,334	2,000,436	1,029,692
Other Operating expenses	353,034	282,813	965,923	589,442
General and administrative	298,566	376,143	898,910	987,861
Depreciation and amortization	124,378	73,518	373,803	187,420
Total operating expenses	1,511,866	1,202,808	4,239,072	2,794,415
Net income (loss) from operations	142,864	-134,184	278,443	-203,542
Other income (expense):	'	'	'	'
Miscellaneous income	750	750	2,313	2,250
Gain (Loss) on change in fair value of derivative liability	-1,631	0	187,351	0
Amortization financing costs	-22,802	-14,337	-51,477	-43,011
Interest expense, net	-302,590	-135,652	-983,966	-372,515
Total other income (expense)	-326,273	-149,239	-845,779	-413,276
Net loss before provision for income taxes	-183,409	-283,423	-558,870	-616,818
Income taxes (benefit)	0	0	0	-23,103
NET LOSS	($183,409)	($283,423)	($558,870)	($593,715)
Net loss per common share, basic and diluted (in dollars per share)	($0.01)	($0.02)	($0.04)	($0.05)
Weighted average number of common shares outstanding, basic and diluted (in shares)	13,416,949	12,706,795	13,005,773	12,623,962

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock Subscriptions [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2012	($1,301,534)	$0	$12,707	$7,244,993	$100,000	($8,659,234)
Balance (in shares) at Dec. 31, 2012	'	0	12,706,795	'	'	'
Common stock issued for services rendered	155,875	0	285	155,590	0	0
Common stock issued for services rendered (in shares)	921,666	0	285,000	'	'	'
Common stock issued for subscription	0	0	66	99,934	-100,000	0
Common stock issued for subscription (in shares)	'	0	66,666	'	'	'
Common stock issued to acquire 10% in MedTech Diagnostics, LLC	450,000	0	1,000	449,000	0	0
Common stock issued to acquire 10% in MedTech Diagnostics, LLC (in shares)	'	0	1,000,000	'	'	'
Common stock issued to acquire patent rights from CFO	286,500	0	637	285,863	0	0
Common stock issued to acquire patent rights from CFO (in shares)	'	0	636,666	'	'	'
Net loss	-558,870	0	0	0	0	-558,870
Balance at Sep. 30, 2013	($968,029)	$0	$14,695	$8,235,380	$0	($9,218,104)
Balance (in shares) at Sep. 30, 2013	'	0	14,695,127	'	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net Loss	($558,870)	($593,715)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Depreciation	373,803	187,420
Amortization of financing costs	51,477	43,011
Amortization of debt discount in connection with convertible note	280,125	0
Stock-based compensation	155,875	0
Loss on change in fair value of debt derivative	-187,351	0
Changes in operating assets and liabilities:	'	'
Accounts receivable	-646,621	-166,447
Accounts receivable-other	0	-205,000
Prepaid expenses and other	-83,256	-72,973
Restricted funds	-37,163	-126,070
Accounts payable and accrued expenses	306,412	231,497
Unearned income	1,322	3,774
Deferred income taxes	0	-23,103
Net cash used in operating activities	-344,247	-721,606
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Cash received from acquisition	0	48,761
Cash payments for acquisition	0	-143,366
Purchase of equipment	-319,762	-2,473,799
Net increase (decrease) in deposits	12,757	-323
Net cash used in investing activities	-307,005	-2,568,727
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Net (payments) proceeds from related party line of credit	-11,882	190,000
Proceeds from convertible note payable	257,000	0
Proceeds from lines of credit	1,086,404	0
Proceeds from notes payable	152,659	2,871,058
Proceeds from common stock subscription	0	100,000
Net payments on notes payable	-702,954	-202,002
Net cash provided by financing activities	781,227	2,959,056
Net increase (decrease) in cash and cash equivalents	129,975	-331,277
Cash and cash equivalents, beginning of period	67,045	528,303
Cash and cash equivalents, end of period	197,020	197,026
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:	'	'
Cash paid during the period for interest	703,841	348,302
Cash paid during the period for taxes	0	0
Supplemental Disclosure on non-cash investing and financing activities:	'	'
Common stock issued in connection with acquisition of First Choice Medical Group, Inc.	0	702,849
Common stock issued in connection with acquisition of patent	286,500	0
Common stock issued to acquire 10% interest in MedTech Diagnostics, LLC	$450,000	$0

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:
	General
	The (a) condensed consolidated balance sheet as of December 31, 2012, which has been derived from the audited financial statements of First Choice Healthcare Solutions, Inc. (“FCHS” and including, where appropriate, its consolidated subsidiaries, the “Company”), and (b) the unaudited condensed consolidated interim financial statements as of September 30, 2013 of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of results that may be expected for the year ending December 31, 2013. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2013.
	Basis of Presentation
	The Company caused a certificate of merger (the “Certificate of Merger”) of Medical Billing Assistance, Inc., a Colorado corporation incorporated on May 30, 2007 (“Medical Billing”), to be filed whereby Medical Billing was merged with and into the Company. The effective date for the Certificate of Merger was April 4, 2012. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the “Reincorporation”). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
	As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split.  Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company.
	On April 2, 2012, the Company completed its acquisition of First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), pursuant to the Membership Interest Purchase Closing Agreement (the “Purchase Agreement”), dated the same date. The Company has been managing the practice of First Choice – Brevard since November 1, 2011, pursuant to a Management Services Agreement (the “Management Agreement”).
	The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc., MTMC of Melbourne, Inc., Marina Towers, LLC, FCID Medical Inc. and First Choice - Brevard. All significant intercompany balances and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Accordingly, actual results could differ from those estimates.
	Patents
	Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company’s intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 shares of the Company’s common stock to a related party (See Note 11). The shares of common stock were valued at $286,500, which was estimated to be approximately the fair value of the patent acquired and did not materially differ from the fair value of the common stock.
	Property and Equipment
	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 20 to 39 years.
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arraignments (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on the Company's financial position and results of operations was not significant.
	Segment Information
	Accounting Standards Codification subtopic Segment Reporting 280-10 (“ASC 280-10”) establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s two principal operating segments (see Note 14 – Segment Information).
	Long-Lived Assets
	The Company follows Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires that assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.
	Patient list
	Patient list is comprised of acquired patients in connection with the acquisition of First Choice - Brevard and is amortized ratably over the estimated useful life of 15 years. Amortization for the three and nine months ended September 30, 2013 was $5,000 and $15,000, respectively, and for the three and nine months ended September 30, 2012 was $5,000 and $10,000, respectively.  Accumulated amortization of patient list costs were $30,000 and $24,391 at September 30, 2013 and December 31, 2012, respectively.
	Cash and Cash Equivalents
	The Company considers cash and cash equivalents to consist of cash on hand and investments having an original maturity of 90 days or less that are readily convertible into cash. As of September 30, 2013, the Company had $197,020 in cash.
	Capitalized Financing Costs
	Capitalized financing costs represent costs incurred in connection with obtaining the debt financing.  These costs are amortized ratably and charged to financing expenses over the term of the related debt. The amortization for the three and nine months ended September 30, 2013 was $22,802 and $51,477, respectively; and for the three and nine months ended September 30, 2012 was $14,337 and $43,011, respectively.  Accumulated amortization of deferred financing costs was $127,940 and $76,464 at September 30, 2013 and December 31, 2012, respectively.
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable.   Generally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
	Accounts Receivable
	Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. Credit for accounts receivable is generally extended on a short-term basis; thus account receivables do not bear interest. Accounts receivable are periodically evaluated for collectability based on a rolling average of cash received as a percentage of gross billing.
	Income Taxes
	The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
	Net Loss Per Share
	The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS.
	Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period.  It excludes the dilutive effects of potentially issuable shares of common stock such as those related to our issued convertible debt, warrants and stock options (calculated using the treasury stock method).   Fully diluted weighted average shares outstanding were 15,628,755 and 12,806,795 for the three months ended September 30, 2013 and 2012, respectively and 15,217,578 and 14,498,962 for the nine months ended September 30, 2013 and 2012, respectively.
	Stock-Based Compensation
	Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.  The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the arms-length private placement transaction nearest the measurement date (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. The measurement date is the earlier of (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete. As of September 30, 2013, the Company had no non-employee options outstanding to purchase shares of common stock.
	Derivative Financial Instruments
	Accounting Standards Codification subtopic 815-40, Derivatives and Hedging, Contracts in Entity’s own Equity (“ASC 815-40”) became effective for the Company on October 1, 2009. Certain of the Company’s convertible debt has conversion provisions based on a discount to the market price of the Company’s common stock.
	Fair Value of Financial Instruments
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2013 and December 31, 2012. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable. Fair values were assumed to approximate carrying values for cash and payables because they are short term in nature and their carrying amounts approximate fair values or they are payable on demand.
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s condensed consolidated financial position, results of operations or cash flows.

LIQUIDITY

LIQUIDITY	9 Months Ended
	Sep. 30, 2013
Liquidity Disclosures [Abstract]	'
Liquidity Disclosure [Text Block]	'
	NOTE 2 — LIQUIDITY
	The Company incurred various non-recurring expenses in 2012 in connection with operating startup costs relating to the acquisition of a medical practice.  Management believes the positive year-end earnings before interest, taxes, depreciation and amortization and the continuing trend of positive growth before interest, taxes, depreciation and amortization through September 30, 2013 will support improved liquidity. Moreover, subsequent to the end of the third quarter 2013 and as further detailed in Note 15 – Subsequent Events, the Company issued and sold to Hillair Capital Investments, L.P. a $2,320,000 8% Original Issue Discount Convertible Debenture, raising net proceeds of $2,000,000 less customary legal and due diligence fees. The Company then paid off or converted to equity a total of $1,238,480 in debt (see Note 15 – Subsequent Events); and modified its $1.5 million line of credit with CT Capital, providing for the reduction of the annual interest rate from 12% per annum to 6% per annum in exchange for the issuance of 100,000 restricted shares of the Company’s common stock.
	The Marina Towers building is fully occupied. The Company believes that ongoing operations of Marina Towers, LLC, the current strong, positive cash balance along with continued execution of its business development plan will allow the Company to further improve its working capital; and that it will have sufficient capital resources to meet projected cash flow requirements through the date that is one year plus a day from the filing date of this report.  However, there can be no assurance that the Company will be successful in fully executing its business development plan.

CASH_RESTRICTED

CASH - RESTRICTED	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents [Abstract]	'
Restricted Cash and Cash Equivalents Disclosure [Text Block]	'
	NOTE 3 — CASH - RESTRICTED
	Cash-restricted is comprised of funds deposited to and held by the mortgage lender for payments of property taxes, insurance, replacements and major repairs of the Company's commercial building. The majority of the restricted funds are reserved for tenant improvements.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT, AND EQUIPMENT	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 4 — PROPERTY, PLANT, AND EQUIPMENT
	Property, plant and equipment at September 30, 2013 and December 31, 2012 are as follows:
			September 30,		December 31,
			2013		2012
	Land	$	1,000,000	$	1,000,000
	Building		3,055,168		3,055,168
	Building improvements		1,758,818		1,691,625
	Medical office improvement		1,410,028		1,410,028
	Automobiles		29,849		29,849
	Computer equipment		188,451		186,549
	Medical equipment		2,204,641		2,039,393
	MRI center		784,999		705,118
	Office equipment		110,378		104,840
			10,542,332		10,222,570
	Less: accumulated depreciation		-1,834,133		-1,465,939
		$	8,708,199	$	8,756,631
	During the three and nine months ended September 30, 2013, depreciation expense charged to operations was $130,885 and $373,803, respectively; and during the three and nine months ended September 30, 2012, depreciation expense charged to operations was $73,538 and $187,420, respectively.

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2013
Equity Method Investments and Joint Ventures [Abstract]	'
Equity Method Investments and Joint Ventures Disclosure [Text Block]	'
	NOTE 5 — INVESTMENTS
	On September 7, 2013, the Company issued an aggregate of 1,000,000 shares of its common stock to acquire a 10% membership interest in MedTech Diagnostics, LLC, a Florida distributor of multi-test medical diagnostic equipment. The investment is recorded at cost, determined at the date of the acquisition, based on the fair value of the underlying issued common shares.

LINES_OF_CREDIT

LINES OF CREDIT	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	NOTE 6 — LINES OF CREDIT
	Line of Credit, CT Capital
	On June 18, 2013, the Company’s subsidiary, First Choice Medical Group of Brevard, LLC, entered into a Loan and Security Agreement (the “Loan Agreement”) with CT Capital. Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership (the “Lender”). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $1,500,000 to First Choice Medical Group of Brevard, LLC with an interest rate of 12% per annum (the “Loan”). The maturity date of the Loan is December 31, 2016 (the “Maturity Date”). Interest shall be due and payable monthly. Upon default, the interest may be adjusted to the highest rate permissible by law. The Loan is secured by the accounts receivable, and assets of the Company’s subsidiary, First Choice Medical Group of Brevard, LLC. The assets constitute the collateral for the repayment of the Loan. The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by Legal Letters of Protection. At any time, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into the common stock of the Company at a price equal to $0.75 per share. The Company did not record an embedded beneficial conversion feature in the note since the fair value of the common stock did not exceed the conversion rate at the date of commitment.
	As detailed in Note 15 – Subsequent Events, on November 8, 2013, in consideration for a fee of 100,000 shares of the Company’s common stock, restricted pursuant to Rule 144, CT Capital agreed to modify the line of credit to the Company’s subsidiary, First Choice Medical Group of Brevard, LLC. Under the loan modification agreement, the annual rate of interest was reduced from 12% per annum to 6% per annum and will remain at 6% until November 1, 2015. All other terms under the June 18, 2013 Loan and Security Agreement will remain the same.
	The obligations of the Company under the Loan Agreement is guaranteed by certain affiliates of the Company, including a personal guarantee issued by the Company’s Chief Executive Officer.
	Line of Credit, MTI Capital
	On May 1, 2013, the Company entered into a loan commitment whereby MTI Capital LLC provided a line of credit up to $2,000,000 in the form of a convertible loan with interest at 12% per annum, payable monthly with principal due two years from the effective date of the loan. On August 28, 2013, the Company amended the loan agreement to change the conversion rate from $0.75 per share to $0.45 per share. At September 30, 2013, there was an outstanding balance of $502,196; however, as detailed in Note 15 – Subsequent Events, on November 8, 2013, MTI converted the then outstanding balance of $624,000 related party principal and interest amount on the loan, into shares of the Company’s common stock at a price equal to $0.45 per share for a total of 1,386,667 shares issued.
	In the third quarter 2013, the Company did not record an embedded beneficial conversion feature in the note since the fair value of the common stock did not exceed the conversion rate at the date of commitment or amendment.

LINE_OF_CREDIT_RELATED_PARTY

LINE OF CREDIT, RELATED PARTY	9 Months Ended
	Sep. 30, 2013
Line Of Credit Facility [Abstract]	'
Line Of Credit Related Party [Text Block]	'
	NOTE 7 — LINE OF CREDIT, RELATED PARTY
	On February 1, 2012, the Company opened a $500,000 unsecured, revolving line of credit loan with CCR of Melbourne, Inc., an entity owned and controlled by the Company's Chief Executive Officer.  The revolving line of credit loan matures on October 1, 2015 with interest at a per annum rate of 8.5% beginning March 1, 2012.  Advances on the line of credit are at the sole discretion of CCR of Melbourne, Inc. As of September 30, 2013, $141,448 was outstanding. The Company accrued $3,883 and $7,089 as related party interest for the three and nine months ended September 30, 2013, respectively. The Company paid $1,391 and $3,331 as related party interest for the three and nine months ended September 30, 2012, respectively.
	As detailed in Note 15 – Subsequent Events, on November 8, 2013, CCR converted the then outstanding balance of $142,483.52, representing all of the outstanding related party principal and interest amount on the loan, into shares of the Company’s common stock at a price equal to $0.45 per share for a total of 316,631 shares issued.

NOTE_PAYABLE_RELATED_PARTY

NOTE PAYABLE, RELATED PARTY	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Note Payable, Related Party Disclosure [Text Block]	'
	NOTE 8 — NOTE PAYABLE, RELATED PARTY
	The Company entered into an unsecured loan agreement with HS Real Company, LLC (“HSR”) on May 17, 2012 for $100,000 at an interest rate of 12% per annum (the "HSR Note"). On August 5, 2012, HSR increased the principal amount to $250,000, and subsequently HSR advanced an additional $50,000 to the Company, bringing the aggregate principal amount of the HSR Note to $300,000, all of which was due and payable to HSR on December 31, 2012. The Company paid $9,290 and $27,642 as interest on the HSR note for the three and nine months ended September 30, 2013, respectively. The Company paid $5,912 and $7,782 as related party interest for the three and nine months ended September 30, 2012, respectively.
	As detailed in Note 15 – Subsequent Events, on November 8, 2013, the Company paid off the HSR Note in full, remitting HSR $300,000 for the outstanding principal and interest balance due on the HSR Note.

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 9 — CONVERTIBLE NOTES PAYABLE
	Convertible notes payable at September 30, 2013 and December 31, 2012 are as follows:
		September 30,		December 31,
		2013		2012
	Note payable, 8% per annum due September 18, 2013, net of unamortized debt discount of $160,543, respectively, including accrued interest	$	-	$	43,537
	Note payable, 8% per annum due May 16, 2014, net of unamortized debt discount of $106,744, including accrued interest		58,098		-
			58,098		43,537
	Less: current portion		-58,098		-43,537
		$	-	$	-
	February 19, 2013 Note Payable
	On February 19, 2013, the Company entered into a Securities Purchase Agreement with an accredited investor (the “Lender”), in reliance upon the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), for the sale of an 8% convertible note in the original principal amount of $103,500 (the “Note”). The total net proceeds the Company received from this offering were $100,000.
	During the nine months ended September 30, 2013, the Company paid in full the above described Note payable.
	The Company identified the embedded derivatives related to the above described Note,  which included certain conversion features and reset provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of the Note and to fair value as of each subsequent reporting date. At the inception of the Note, the Company determined the aggregate fair value of $97,577 of embedded derivatives. The fair value of the embedded derivatives was determined using the Binomial Lattice Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 98.67%, (3) weighted average risk-free interest rate of 0.17 % (4) expected life of 0.75 years, and (5) estimated fair value of the Company’s common stock of $1.94 per share. The determined fair value of the debt derivative of $97,577 was charged as a debt discount to the Note.
	The charge of the amortization of debt discount for the three and nine months ended September 30, 2013 was $51,095 and $97,577, respectively. During the nine months ended September 30, 2013, the Company recorded a net gain on change in fair value of derivative liability relating to the above described note of $97,577.
	August 14, 2013 Note Payable
	On August 14, 2013, the Company entered into a Securities Purchase Agreement with an accredited investor (the “Lender”), in reliance upon the exemption from registration under Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), for the sale of an 8% convertible note in the original principal amount of $153,500 (the “Note”). The total net proceeds the Company received from this offering were $151,000.
	As detailed in Note 15 – Subsequent Events, on November 8, 2013, the Company retired the Note due the Lender originally due on November 21, 2013. The Company paid the Lender $188,850 in principal and interest, and accordingly recorded a gain from change in fair value of debt derivative of $171,987.
	The Company identified the embedded derivatives related to the above described Note, which included certain conversion features and reset provisions. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of the Note and to fair value as of each subsequent reporting date. At the inception of the Note, the Company determined the aggregate fair value of $128,748 of embedded derivatives. The fair value of the embedded derivatives was determined using the Binomial Lattice Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 119.96%, (3) weighted average risk-free interest rate of 0.12 % (4) expected life of 0.75 years, and (5) estimated fair value of the Company’s common stock of $0.60 per share. The determined fair value of the debt derivative of $128,748 was charged as a debt discount to the Note.
	At September 30, 2013, the Company marked to market the fair value of the debt derivatives contained in the Company’s convertible note and determined the aggregate fair value to be $210,961. The Company recorded a loss from change in fair value of debt derivatives of $82,213 for the nine months ended September 30, 2013 relating to the above described note. The fair value of the embedded derivatives was determined using Binomial Lattice Option Pricing Model based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 134.94%, (3) weighted average risk-free interest rate of 0.04%, (4) expected life of 0.62 years, and (5) estimated fair value of the Company’s common stock of $1.34 per share.
	The charge of the amortization of debt discount and costs for the three and nine months ended September 30, 2013 was $22,004 and $280,125, respectively.

NOTES_PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Long-term Debt [Text Block]	'
	NOTE 10 — NOTES PAYABLE
	Notes payable as of September 30, 2013 and December 31, 2012 are comprised of the following:
		September 30,		December 31,
		2013		2012
	Mortgage payable	$	7,377,028	$	7,444,580
	Note payable, GE Capital (construction), MRI		346,226		450,604
	Note payable, GE Capital (construction), 2		114,378		153,340
	Note Payable, GE Capital (MRI)		1,647,155		1,806,932
	Note Payable, GE Capital (X-ray)		193,904		213,126
	Note Payable, GE Arm		119,999		-
	Note payable, Auto		23,560		27,300
	Capital lease, Equipment		35,337		-
	Note payable, Dr. Richard Newman		-		5,000
			9,857,587		10,100,882
	Less: current portion		-738,349		-690,586
		$	9,119,238	$	9,410,296
	Mortgage Payable
	On August 12, 2011, the Company refinanced its existing mortgage note payable as described below providing additional working capital funds. The aggregate amount of the note of $7,550,000 bears 6.10% interest per annum with monthly payments of $45,752.61 beginning in October 2011 based on a 30 year amortization schedule with all remaining principal and interest due in full on September 16, 2016.  The note is secured by land and the building along with first priority assignment of leases and rents.  Tenant rents are mailed to lockbox operated by the mortgage service company.  In addition, the Company's Chief Executive Officer provided a limited personal guaranty.
	In connection with the refinancing of the mortgage note payable, the Company incurred financing costs of $286,723.  The capitalized financing costs are amortized ratably over the term of the mortgage note payable.
	Note Payable – Equipment Financing
	On May 21, 2012, the Company completed a financing with GE Healthcare Financial Services (“GE Capital”) for approximately $2.4 million.
	As of September 30, 2012, the Company had drawn down a total of $450,000 against the first construction loan. This construction loan is payable in 35 monthly payments (first three payments are $nil) including interest at 7.38%, beginning the earlier of a) December 2012 or b) total advances have been made in the amount of $450,000.
	On September 24, 2012, the Company drew down a total of $150,000 against the second construction loan. This construction loan is payable in 35 monthly payments (first three payments are $nil) including interest at 7.38%, beginning the earlier of a) December 2012 or b) total advances have been made in the amount of $150,000.
	The Company entered into an aggregate of $2,288,679 equipment finance leases subject to delivery and acceptance. All notes and finance leases have been personally guaranteed by the Company's Chief Executive Officer.
	On August 22, 2012, the Company accepted the delivery of x-ray equipment under the equipment finance leases discussed above. As such, the component piece accepted of $212,389 is due over 60 months at $-0- the first three months; $4,300 for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the finance lease to interest only payments of $1,384 for three months; $4,575 for the remaining 56 monthly payments.
	On September 27, 2012, the Company accepted the delivery of MRI equipment under the equipment finance leases discussed above. As such, the component piece accepted of $1,771,390 is due over 60 months at $-0- the first three months; $38,152 for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the finance lease to interest only payments of $11,779 for three months; $38,152 for the remaining 56 monthly payments.
	On February 25, 2013, the Company accepted the delivery of C-arm equipment under the equipment finance leases discussed above. As such, the component piece accepted of $117,322 is due over 63 months at $-0- the first three months; $2,388 for the remaining 60 months including interest at 7.39% per annum.
	Note Payable – Auto
	On May 21, 2012, the Company issued a note payable, in the amount of $29,850, due in monthly installments of $593 including interest of 6.99%, due to mature in June 2017, and secured by related equipment.
	Capital Lease – Equipment
	On June 11, 2013, the Company entered into a lease agreement to acquire equipment with 48 monthly payments of $956.45 payable through June 1, 2017 with an effective interest rate of 14.002% per annum. The Company may elect to acquire the leased equipment at a nominal amount at the end of the lease.
	Note Payable – Newman
	In January 2013, the following note was paid in full.
	In connection with the acquisition of First Choice – Brevard as described in Note 1 above, the Company assumed a $45,000 non-interest bearing, unsecured note payable to Dr. Richard Newman at $5,000 per month, maturing on January 1, 2013.
	Aggregate maturities of long-term debt as of September 30, 2013 are as follows:
		Amount
	Three months ended December 31, 2013	$	413,780
	Year ended December 31, 2014		740,543
	Year ended December 31, 2015		719,433
	Year ended December 31, 2016 and after		7,983,831
	Total	$	9,857,587

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 11 — RELATED PARTY TRANSACTIONS
	As more fully described in Note 7 – Line of Credit, Related Party above, CCR of Melbourne, Inc., an entity owned and controlled by the Company’s Chief Executive Officer, provided a $500,000 unsecured, revolving line of credit to the Company. As of September 30, 2013, $141,448 was outstanding. The Company accrued $3,883 and $7,089 as related party interest for the three and nine months ended September 30, 2013, respectively. As further detailed in Note 15 – Subsequent Events, on November 8, 2013, CCR converted the outstanding balance of $142,483.52, representing all of the outstanding related party principal and interest amount on the loan, into shares of the Company’s common stock at a price equal to $0.45 per share for a total of 316,631 shares issued.
	As more fully described in Note 8 – Note Payable, Related Party above, the Company entered into an unsecured loan agreement with HS Real Company, LLC (“HSR”) on May 17, 2012 for $100,000 at an interest rate of 12% per annum (the "HSR Note"). On August 5, 2012, HSR increased the principal amount to $250,000, and subsequently HSR advanced an additional $50,000 to the Company, bringing the aggregate principal amount of the HSR Note to $300,000, all of which was due and payable to HSR on December 31, 2012. The Company paid $9,290 and $27,642 as interest on the HSR note for the three and nine months ended September 30, 2013, respectively. Mr. Colin Halpern is both an Affiliate of HSR and a member of the Board of Directors of First Choice Healthcare Solutions, Inc. As further detailed in Note 15 – Subsequent Events, on November 8, 2013, the Company paid off the HSR Note, remitting HSR $300,000 for the outstanding principal and interest balance due on the HSR Note.
	On September 7, 2013, the Company issued 636,666 shares of its common stock to Donald Bittar, the Company’s Chief Financial Officer to acquire a patent for a medical device he invented. The patent was valued at $286,500, which was estimated to be approximate fair value of the patent acquired and did not materially differ from the fair value of the common stock.

CAPITAL_STOCK

CAPITAL STOCK	9 Months Ended
	Sep. 30, 2013
Capital Stock [Abstract]	'
Capital Stock [Text Block]	'
	NOTE 12 — CAPITAL STOCK
	During the nine months ended September 2013, the Company issued the following shares of common stock, restricted pursuant to Rule 144, to certain officers, directors, employees and professional service providers for services rendered:
	Shares Issued To	Number of Shares Issued
	Board of Directors		105,000
	Officers and Employees1		756,666
	Professional Service Providers		60,000
	Total		921,666
	1 As detailed in Note 11 - Related Party Transactions above, shares issued to Officers and Employees includes 636,666 shares of common stock issued to Donald Bittar, the Company's CFO, to acquire a patent.
	The shares were issued at fair market value on the date of service and their market value on date of issuance.

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	9 Months Ended
	Sep. 30, 2013
Stock Options and Warrants Disclosure [Abstract]	'
Stock Options and Warrants Disclosure [Text Block]	'
	NOTE 13 — STOCK OPTIONS AND WARRANTS
	Warrants
	The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company's common stock as of September 30, 2013:
			Warrants Outstanding					Warrants Exercisable
						Weighted			Weighted
	Price		Outstanding	Expiration Date		Price		Exercisable	Price
	$	3.6	1,875,000	31-Dec-16		$	3.6	1,875,000	$	3.6
	Transactions involving stock warrants issued to non-employees are summarized as follows:
					Weighted
					Average
			Number of		Price
			Shares		Per Share
	Outstanding at December 31, 2011:		1,875,000	$	3.6
	Granted		-		-
	Exercised		-		-
	Expired		-		-
	Outstanding at December 31, 2012:		1,875,000		3.6
	Granted		-		-
	Exercised		-		-
	Expired		-		-
	Outstanding at September 30, 2013:		1,875,000	$	3.6
	As of September 30, 2013, the Company had no outstanding options.

SEGMENT_REPORTING

SEGMENT REPORTING	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	NOTE 14 — SEGMENT REPORTING
	The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has two reportable segments: Marina Towers, LLC and FCID Medical, Inc.
	The Marina Towers, LLC segment derives revenue from the operating leases of its owned building, whereas FCID Medical segment derives revenue for medical services provided to patients.
	Information concerning the operations of the Company's reportable segments is as follows:
	Summary Statement of Operations for the three months ended September 30, 2013:
			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	1,395,610		$	-		$	-		$	1,395,610
	Rental revenue			365,839			-			-			-106,719			259,120
	Total Revenue			365,839			1,395,610			-			-106,719			1,654,730
	Operating expenses:
	Salaries & benefits			3,000			574,487			158,401			-			735,888
	Other operating expenses			95,689			357,696			-			-100,351			353,034
	General and administrative			21,791			140,039			136,736			-			298,566
	Depreciation and amortization			41,571			91,272			-			-			132,843
	Total operating expenses			162,051			1,163,494			295,137			-100,351			1,520,331
	Net income (loss) from operations:			203,788			232,116			-295,137			-6,368			134,399
	Interest expense			-115,241			-78,039			-109,310			-			-302,590
	Amortization of financing costs			-14,337			-			-			-			-14,337
	Gain on change in derivative liability			-			-			-1,631			-			-1,631
	Other income (expense)			750			-			-			-			750
	Net Income (loss):			74,960			154,077			-406,078			-6,368			-183,409
	Income taxes			-			-			-			-			-
	Net income (loss)		$	74,960		$	154,077		$	-406,078		$	-6,368		$	-183,409
	Summary Statement of Operations for the three months ended September 30, 2012:
			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	798,077		$	-		$	-		$	798,077
	Rental Revenue			364,081			-			-			-93,534			270,547
	Total Revenue			364,081			798,077			-			-93,534			1,068,624
	Operating expenses:
	Salaries and benefits			3,000			406,055			61,279						470,334
	Other operating expenses			111,449			319,039						-147,675			282,813
	General and administrative			10,019			173,525			138,458			54,141			376,143
	Depreciation and amortization			40,365			33,153			-			-			73,518
	Total operating expenses			164,833			931,772			199,737			-93,534			1,202,808
	Net income (loss) from operations:			199,248			-133,695			-199,737			-			-134,184
	Interest expense			-116,576			-16,989			-2,087			-			-135,652
	Amortization of finance costs			-14,337			-			-			-			-14,337
	Other income (expense)			750			-			-			-			750
	Net Income (loss):			69,085			-150,684			-201,824			-			-283,423
	Income taxes			-			-			-			-			-
	Net income (loss)		$	69,085		$	-150,684		$	-201,824		$	-		$	-283,423
	Summary Statement of Operations for the nine months ended September 30, 2013:
			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	3,739,435		$	-		$	-		$	3,739,435
	Rental revenue			1,104,405			-			-			-317,859			786,546
	Total Revenue			1,104,405			3,739,435			-			-317,859			4,525,981
	Operating expenses:
	Salaries & benefits			9,000			1,583,238			408,198			-			2,000,436
	Other operating expenses			289,765			994,017			-			-317,859			965,923
	General and administrative			61,132			447,024			390,755			-			898,911
	Depreciation and amortization			123,313			258,955			-			-			382,268
	Total operating expenses			483,210			3,283,234			798,953			-317,859			4,247,538
	Net income (loss) from operations:			621,195			456,201			-798,953			-			278,443
	Interest expense			-347,406			-208,773			-427,787			-			-983,966
	Amortization of financing costs			-43,011			-			-			-			-43,011
	Gain on change in derivative liability			-			-			187,351			-			187,351
	Other income (expense)			2,313			-			-			-			2,313
Net Income (loss):			233,091			247,428			-1,039,389			-			-558,870
Income taxes			-			-			-			-			-
Net income (loss)		$	233,091		$	247,428		$	-1,039,389		$	-		$	-558,870
Summary Statement of Operations for the nine months ended September 30, 2012:
		Marina			FCID						Intercompany
		Towers			Medical			Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue		$	-		$	1,707,694		$	-		$	-		$	1,707,694
Rental Revenue			1,094,466			-			-			-211,287			883,179
Total Revenue			1,094,466			1,707,694			-			-211,287			2,590,873
Operating expenses:
Salaries and benefits			9,000			795,375			225,317						1,029,692
Other operating expenses			289,937			510,792						-211,287			589,442
General and administrative			52,983			408,162			526,716						987,861
Depreciation and amortization			121,095			66,325			-			-			187,420
Total operating expenses			473,015			1,780,654			752,033			-211,287			2,794,415
Net income (loss) from operations:			621,451			-72,960			-752,033			-			-203,542
Interest expense			-348,227			-18,858			-5,430			-			-372,515
Amortization of finance costs			-43,011			-			-			-			-43,011
Other income (expense)			2,250			-			-			-			2,250
Net Income (loss):			232,463			-91,818			-757,463			-			-616,818
Income taxes			-8,707			3,439			28,371			-			23,103
Net income (loss)		$	223,756		$	-88,379		$	-729,092		$	-		$	-593,715
Assets:
	Marina			FCID						Intercompany
	Towers			Medical			Corporate			Eliminations			Total
Assets:
At September 30, 2013:	$	4,878,723		$	5,947,558		$	883,750		$	-		$	11,710,031
At December 31, 2012:	$	4,938,954		$	5,183,592		$	8,702		$	-		$	10,131,248
Assets acquired
Three months ended September 30, 2013	$	-		$	54,255		$	-		$	-		$	54,255
Three months ended September 30, 2012	$	-		$	2,283,431		$	-		$	-		$	2,283,431
Nine months ended September 30, 2013	$	67,192		$	261,035		$	-		$	-		$	328,227
Nine months ended September 30, 2012	$	-		$	2,473,799		$	-		$	-		$	2,473,799

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 15 — SUBSEQUENT EVENTS
	Hillair Capital Investments, L.P.
	On November 8, 2013, First Choice Healthcare Solutions, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Hillair Capital Investments L.P. ("Hillair") whereby the Company issued and sold (the “Debenture and Warrant Transaction”) to Hillair (i) a $2,320,000, 8% Original Issue Discount Convertible Debenture due December 28, 2013, subject to extension through November 1, 2015 (the “Debenture”), and (ii) a Common Stock Purchase Warrant (the “Warrant”) to purchase up to 2,320,000 shares of the Company’s common stock (the “Common Stock”). The closing of the Debenture and Warrant Transaction occurred on November 8, 2013 (“Original Issue Date”).
	The Company issued to Hillair the Debenture and the Warrant for the purchase price of $2,000,000. At any time after the Original Issue Date until the Debenture is no longer outstanding, the Debenture shall be convertible, in whole or in part, into shares of Common Stock at the option of Hillair, subject to certain conversion limitations set forth in the Debenture. The Company, however, has reserved the right to pay the Debenture in cash. The conversion price for the Debenture is initially $1.00 per share, subject to adjustment upon certain events, as set forth in the Debenture. Hillair may not convert the Debenture into shares of common stock below $1.00 per share provided the Company abides by the conditions set forth in the Debenture, including, but not limited to, that the Company has not issued any securities below $1.00 per share and is able to pay all of its financial obligations in cash.
	Interest on the Debenture accrues at the rate of 8% annually and is payable quarterly on August 1, November 1, February 1, and May 1, beginning on August 1, 2014, on any redemption, conversion and at maturity. Interest is payable in cash or at the Company’s option in shares of the Company’s common stock; provided certain conditions are met. Commencing on February 1, 2015, the Company will be obligated to redeem a certain amount under the Debenture on a quarterly basis, in an amount equal to 580,000, plus accrued but unpaid interest and any other amounts then owed to the holder of the Debenture as further set forth therein on each of February 1, 2015, May 1, 2015, August 1, 2015 and November 1, 2015 (the “Required Redemption Amount”) for each quarter, until the Debenture’s maturity date of November 1, 2015.
	Commencing six (6) months after November 8, 2013, the Company may elect to prepay, without penalty, any portion of the principal amount of the Debenture, subject to providing advance notice to the holder of the Debenture, at 120% of the then outstanding principal amount of the Debenture, plus accrued but unpaid interest and any other amounts then owed to the holder of the Debenture as further set forth therein, subject to certain conditions set forth in the Debenture.
	The Warrants may be exercised at any time on or after November 8, 2013 and on or prior to the close of business on June 27, 2017, at an exercise price of $1.35 per share, subject to adjustment upon certain events.
	To secure the Company’s obligations under the Debenture, the Company granted Hillair a security interest in certain of its and its subsidiaries’ assets in the Company as described in the Security Agreement. In addition, certain of the Company’s subsidiaries agreed to guarantee the Company’s obligations pursuant to the Subsidiary Guarantees.
	A summary of the use of proceeds received by the Company in the Hillair transaction is as follows:
	Payment in Full of Balance Due on HSR Note (See Notes 8 & 15)	$	300,000.00
	Payment in Full of Balance Due on Accredited Investor Loan (See Notes 9 & 15)		188,850.00
	Legal and Due Diligence Fees Associated with Hillair Transaction	$	98,003.85
	Expansion and Working Capital	$	1,413,146.15
	TOTAL PROCEEDS RECEIVED FROM HILLAIR	$	2,000,000.00
	HS Real Company, LLC
	As more fully described in Note 8 – Note Payable, Related Party, the Company entered into an unsecured loan agreement with HS Real Company, LLC (“HSR”) on May 17, 2012 for $100,000 at an interest rate of 12% per annum (the "HSR Note"). On August 5, 2012, HSR increased the principal amount to $250,000, and subsequently HSR advanced an additional $50,000 to the Company, bringing the aggregate principal amount of the HSR Note to $300,000, all of which was due and payable to HSR on December 31, 2012. On November 8, 2013, the Company paid off the HSR Note, remitting HSR $300,000 for the outstanding principal and interest balance due on the HSR Note.
	Accredited Investor Loan
	As more fully described in Note 9 – Convertible Notes Payable, on November 8, 2013, the Company retired the Note due an accredited investor originally due on November 21, 2013. The Company paid the Lender $188,850 in principal and interest, and accordingly recorded a gain from change in fair value of debt derivative of $171,987.
	CCR of Melbourne, Inc.
	As more fully described in Note 7 – Line of Credit, Related Party, on February 1, 2012, the Company opened a $500,000 unsecured, revolving line of credit loan with CCR of Melbourne, Inc., an entity owned and controlled by the Company's Chief Executive Officer. The revolving line of credit loan matures on October 1, 2015 with interest at a per annum rate of 8.5% beginning March 1, 2012. Advances on the line of credit are at the sole discretion of CCR of Melbourne, Inc. As of September 30, 2013, $141,448.19 was outstanding. On November 8, 2013, CCR converted the outstanding balance of $142,483.52, representing all of the outstanding related party principal and interest amount on the loan, into shares of the Company’s common stock at a price equal to $0.45 per share for a total of 316,631 shares to be issued.
	MTI Capital, LLC
	As more fully described in Note 6 – Lines of Credit, on May 1, 2013, the Company entered into a loan commitment whereby MTI Capital, LLC (“MTI” or the “Lender”) provided a line of credit up to $2,000,000 in the form of a convertible loan with interest at 12% per annum, payable monthly with principal due two years from the effective date of the loan. There was an outstanding balance of $505,325.91  including principal and interest as of September 30, 2013. At any time, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into the common stock of the Company at a price equal to 0.45 per share. Advances on the line of credit are at the sole discretion of MTI. The Company did not record an embedded beneficial conversion feature in the note since the fair value of the common stock did not exceed the conversion rate at the date of commitment. On November 8, 2013, MTI converted the outstanding balance of $624,000 related party principal and interest amount on the loan, into shares of the Company’s common stock at a price equal to $0.45 per share for a total of 1,386,667 shares to be issued.
	CT Capital LTD
	On November 8, 2013, in consideration for a fee of 100,000 shares of the Company’s common stock, to be issued subject to SEC Rule 144, CT Capital agreed to modify the line of credit to the Company’s subsidiary, First Choice Medical Group of Brevard, LLC. Under the loan modification agreement, the annual rate of interest was reduced from 12% per annum to 6% per annum and will remain at 6% until November 1, 2015. All other terms under the June 18, 2013 Loan and Security Agreement will remain the same.
	Hanover|Elite
	On October 2, 2013, the Company entered into an agreement to engage the services of Elite Financial Communications Group, LLC, d/b/a Hanover|Elite. The terms of the agreement provide for a monthly retainer of a $6,000 and 300,000 shares of the Company’s common stock, subject to SEC Rule 144 restrictions, which shall be earned and issued quarterly as follows: 37,500 shares on January 3, 2014; 37,500 shares on April 3, 2014; 37,500 shares on July 3, 2014; and 187,500 shares on October 3, 2014.
	As the Company’s investor and public relations counsel of record, Hanover|Elite will collaborate with management on developing, implementing and supporting a fully integrated corporate and shareholder communications platform; and generating meaningful awareness among and measurable support from the retail and institutional investment banking community for the Company, its compelling business plan and promising future growth potential. Jim Hock, Co-Managing Partner of Hanover|Elite and Co-Chairman of the National Investment Banking Association, will lead the IR/PR effort for the Company.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The Company caused a certificate of merger (the “Certificate of Merger”) of Medical Billing Assistance, Inc., a Colorado corporation incorporated on May 30, 2007 (“Medical Billing”), to be filed whereby Medical Billing was merged with and into the Company. The effective date for the Certificate of Merger was April 4, 2012. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the “Reincorporation”). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
	As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split.  Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company.
	On April 2, 2012, the Company completed its acquisition of First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), pursuant to the Membership Interest Purchase Closing Agreement (the “Purchase Agreement”), dated the same date. The Company has been managing the practice of First Choice – Brevard since November 1, 2011, pursuant to a Management Services Agreement (the “Management Agreement”).
	The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc., MTMC of Melbourne, Inc., Marina Towers, LLC, FCID Medical Inc. and First Choice - Brevard. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Accordingly, actual results could differ from those estimates.
Patents, Policy [Policy Text Block]	'
	Patents
	Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company’s intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 shares of the Company’s common stock to a related party (See Note 11). The shares of common stock were valued at $286,500, which was estimated to be approximately the fair value of the patent acquired and did not materially differ from the fair value of the common stock.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 20 to 39 years.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arraignments (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on the Company's financial position and results of operations was not significant.
Segment Reporting, Policy [Policy Text Block]	'
	Segment Information
	Accounting Standards Codification subtopic Segment Reporting 280-10 (“ASC 280-10”) establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s two principal operating segments (see Note 14 – Segment Information).
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	'
	Long-Lived Assets
	The Company follows Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). The Statement requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires that assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.
Patient List [Policy Text Block]	'
	Patient list
	Patient list is comprised of acquired patients in connection with the acquisition of First Choice - Brevard and is amortized ratably over the estimated useful life of 15 years. Amortization for the three and nine months ended September 30, 2013 was $5,000 and $15,000, respectively, and for the three and nine months ended September 30, 2012 was $5,000 and $10,000, respectively.  Accumulated amortization of patient list costs were $30,000 and $24,391 at September 30, 2013 and December 31, 2012, respectively.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers cash and cash equivalents to consist of cash on hand and investments having an original maturity of 90 days or less that are readily convertible into cash. As of September 30, 2013, the Company had $197,020 in cash.
Capitalized Financing Cost [Policy Text Block]	'
	Capitalized Financing Costs
	Capitalized financing costs represent costs incurred in connection with obtaining the debt financing.  These costs are amortized ratably and charged to financing expenses over the term of the related debt. The amortization for the three and nine months ended September 30, 2013 was $22,802 and $51,477, respectively; and for the three and nine months ended September 30, 2012 was $14,337 and $43,011, respectively.  Accumulated amortization of deferred financing costs was $127,940 and $76,464 at September 30, 2013 and December 31, 2012, respectively.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentrations of Credit Risk
	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable.   Generally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	'
	Accounts Receivable
	Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. Credit for accounts receivable is generally extended on a short-term basis; thus account receivables do not bear interest. Accounts receivable are periodically evaluated for collectability based on a rolling average of cash received as a percentage of gross billing.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss Per Share
	The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS.
	Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period.  It excludes the dilutive effects of potentially issuable shares of common stock such as those related to our issued convertible debt, warrants and stock options (calculated using the treasury stock method).   Fully diluted weighted average shares outstanding were 15,628,755 and 12,806,795 for the three months ended September 30, 2013 and 2012, respectively and 15,217,578 and 14,498,962 for the nine months ended September 30, 2013 and 2012, respectively.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.  The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the arms-length private placement transaction nearest the measurement date (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. The measurement date is the earlier of (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete. As of September 30, 2013, the Company had no non-employee options outstanding to purchase shares of common stock.
Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments
	Accounting Standards Codification subtopic 815-40, Derivatives and Hedging, Contracts in Entity’s own Equity (“ASC 815-40”) became effective for the Company on October 1, 2009. Certain of the Company’s convertible debt has conversion provisions based on a discount to the market price of the Company’s common stock.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2013 and December 31, 2012. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash and accounts payable. Fair values were assumed to approximate carrying values for cash and payables because they are short term in nature and their carrying amounts approximate fair values or they are payable on demand.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s condensed consolidated financial position, results of operations or cash flows.

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT, AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property, plant and equipment at September 30, 2013 and December 31, 2012 are as follows:
			September 30,		December 31,
			2013		2012
	Land	$	1,000,000	$	1,000,000
	Building		3,055,168		3,055,168
	Building improvements		1,758,818		1,691,625
	Medical office improvement		1,410,028		1,410,028
	Automobiles		29,849		29,849
	Computer equipment		188,451		186,549
	Medical equipment		2,204,641		2,039,393
	MRI center		784,999		705,118
	Office equipment		110,378		104,840
			10,542,332		10,222,570
	Less: accumulated depreciation		-1,834,133		-1,465,939
		$	8,708,199	$	8,756,631

CONVERTIBLE_NOTES_PAYABLE_Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
	Convertible notes payable at September 30, 2013 and December 31, 2012 are as follows:
		September 30,		December 31,
		2013		2012
	Note payable, 8% per annum due September 18, 2013, net of unamortized debt discount of $160,543, respectively, including accrued interest	$	-	$	43,537
	Note payable, 8% per annum due May 16, 2014, net of unamortized debt discount of $106,744, including accrued interest		58,098		-
			58,098		43,537
	Less: current portion		-58,098		-43,537
		$	-	$	-

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Instruments [Table Text Block]	'
	Notes payable as of September 30, 2013 and December 31, 2012 are comprised of the following:
		September 30,		December 31,
		2013		2012
	Mortgage payable	$	7,377,028	$	7,444,580
	Note payable, GE Capital (construction), MRI		346,226		450,604
	Note payable, GE Capital (construction), 2		114,378		153,340
	Note Payable, GE Capital (MRI)		1,647,155		1,806,932
	Note Payable, GE Capital (X-ray)		193,904		213,126
	Note Payable, GE Arm		119,999		-
	Note payable, Auto		23,560		27,300
	Capital lease, Equipment		35,337		-
	Note payable, Dr. Richard Newman		-		5,000
			9,857,587		10,100,882
	Less: current portion		-738,349		-690,586
		$	9,119,238	$	9,410,296
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	Aggregate maturities of long-term debt as of September 30, 2013 are as follows:
		Amount
	Three months ended December 31, 2013	$	413,780
	Year ended December 31, 2014		740,543
	Year ended December 31, 2015		719,433
	Year ended December 31, 2016 and after		7,983,831
	Total	$	9,857,587

CAPITAL_STOCK_Tables

CAPITAL STOCK (Tables)	9 Months Ended
	Sep. 30, 2013
Capital Stock [Abstract]	'
Schedule Of Stock Issued For Services [Table Text Block]	'
	During the nine months ended September 2013, the Company issued the following shares of common stock, restricted pursuant to Rule 144, to certain officers, directors, employees and professional service providers for services rendered:
	Shares Issued To	Number of Shares Issued
	Board of Directors		105,000
	Officers and Employees1		756,666
	Professional Service Providers		60,000
	Total		921,666
	1 As detailed in Note 11 - Related Party Transactions above, shares issued to Officers and Employees includes 636,666 shares of common stock issued to Donald Bittar, the Company's CFO, to acquire a patent.

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2013
Stock Options and Warrants Disclosure [Abstract]	'
Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]	'
	The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company's common stock as of September 30, 2013:
			Warrants Outstanding					Warrants Exercisable
						Weighted			Weighted
	Price		Outstanding	Expiration Date		Price		Exercisable	Price
	$	3.6	1,875,000	31-Dec-16		$	3.6	1,875,000	$	3.6
Schedule Of Warrants Outstanding and Related Prices [Table Text Block]	'
	Transactions involving stock warrants issued to non-employees are summarized as follows:
					Weighted
					Average
			Number of		Price
			Shares		Per Share
	Outstanding at December 31, 2011:		1,875,000	$	3.6
	Granted		-		-
	Exercised		-		-
	Expired		-		-
	Outstanding at December 31, 2012:		1,875,000		3.6
	Granted		-		-
	Exercised		-		-
	Expired		-		-
	Outstanding at September 30, 2013:		1,875,000	$	3.6

SEGMENT_REPORTING_Tables

SEGMENT REPORTING (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	NOTE 14 — SEGMENT REPORTING
	The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has two reportable segments: Marina Towers, LLC and FCID Medical, Inc.
	The Marina Towers, LLC segment derives revenue from the operating leases of its owned building, whereas FCID Medical segment derives revenue for medical services provided to patients.
	Information concerning the operations of the Company's reportable segments is as follows:
	Summary Statement of Operations for the three months ended September 30, 2013:
			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	1,395,610		$	-		$	-		$	1,395,610
	Rental revenue			365,839			-			-			-106,719			259,120
	Total Revenue			365,839			1,395,610			-			-106,719			1,654,730
	Operating expenses:
	Salaries & benefits			3,000			574,487			158,401			-			735,888
	Other operating expenses			95,689			357,696			-			-100,351			353,034
	General and administrative			21,791			140,039			136,736			-			298,566
	Depreciation and amortization			41,571			91,272			-			-			132,843
	Total operating expenses			162,051			1,163,494			295,137			-100,351			1,520,331
	Net income (loss) from operations:			203,788			232,116			-295,137			-6,368			134,399
	Interest expense			-115,241			-78,039			-109,310			-			-302,590
	Amortization of financing costs			-14,337			-			-			-			-14,337
	Gain on change in derivative liability			-			-			-1,631			-			-1,631
	Other income (expense)			750			-			-			-			750
	Net Income (loss):			74,960			154,077			-406,078			-6,368			-183,409
	Income taxes			-			-			-			-			-
	Net income (loss)		$	74,960		$	154,077		$	-406,078		$	-6,368		$	-183,409
	Summary Statement of Operations for the three months ended September 30, 2012:
			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	798,077		$	-		$	-		$	798,077
	Rental Revenue			364,081			-			-			-93,534			270,547
	Total Revenue			364,081			798,077			-			-93,534			1,068,624
	Operating expenses:
	Salaries and benefits			3,000			406,055			61,279						470,334
	Other operating expenses			111,449			319,039						-147,675			282,813
	General and administrative			10,019			173,525			138,458			54,141			376,143
	Depreciation and amortization			40,365			33,153			-			-			73,518
	Total operating expenses			164,833			931,772			199,737			-93,534			1,202,808
	Net income (loss) from operations:			199,248			-133,695			-199,737			-			-134,184
	Interest expense			-116,576			-16,989			-2,087			-			-135,652
	Amortization of finance costs			-14,337			-			-			-			-14,337
	Other income (expense)			750			-			-			-			750
	Net Income (loss):			69,085			-150,684			-201,824			-			-283,423
	Income taxes			-			-			-			-			-
	Net income (loss)		$	69,085		$	-150,684		$	-201,824		$	-		$	-283,423
	Summary Statement of Operations for the nine months ended September 30, 2013:
			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	3,739,435		$	-		$	-		$	3,739,435
	Rental revenue			1,104,405			-			-			-317,859			786,546
	Total Revenue			1,104,405			3,739,435			-			-317,859			4,525,981
	Operating expenses:
	Salaries & benefits			9,000			1,583,238			408,198			-			2,000,436
	Other operating expenses			289,765			994,017			-			-317,859			965,923
	General and administrative			61,132			447,024			390,755			-			898,911
	Depreciation and amortization			123,313			258,955			-			-			382,268
	Total operating expenses			483,210			3,283,234			798,953			-317,859			4,247,538
	Net income (loss) from operations:			621,195			456,201			-798,953			-			278,443
	Interest expense			-347,406			-208,773			-427,787			-			-983,966
	Amortization of financing costs			-43,011			-			-			-			-43,011
	Gain on change in derivative liability			-			-			187,351			-			187,351
	Other income (expense)			2,313			-			-			-			2,313
Net Income (loss):			233,091			247,428			-1,039,389			-			-558,870
Income taxes			-			-			-			-			-
Net income (loss)		$	233,091		$	247,428		$	-1,039,389		$	-		$	-558,870
Summary Statement of Operations for the nine months ended September 30, 2012:
		Marina			FCID						Intercompany
		Towers			Medical			Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue		$	-		$	1,707,694		$	-		$	-		$	1,707,694
Rental Revenue			1,094,466			-			-			-211,287			883,179
Total Revenue			1,094,466			1,707,694			-			-211,287			2,590,873
Operating expenses:
Salaries and benefits			9,000			795,375			225,317						1,029,692
Other operating expenses			289,937			510,792						-211,287			589,442
General and administrative			52,983			408,162			526,716						987,861
Depreciation and amortization			121,095			66,325			-			-			187,420
Total operating expenses			473,015			1,780,654			752,033			-211,287			2,794,415
Net income (loss) from operations:			621,451			-72,960			-752,033			-			-203,542
Interest expense			-348,227			-18,858			-5,430			-			-372,515
Amortization of finance costs			-43,011			-			-			-			-43,011
Other income (expense)			2,250			-			-			-			2,250
Net Income (loss):			232,463			-91,818			-757,463			-			-616,818
Income taxes			-8,707			3,439			28,371			-			23,103
Net income (loss)		$	223,756		$	-88,379		$	-729,092		$	-		$	-593,715
Assets:
	Marina			FCID						Intercompany
	Towers			Medical			Corporate			Eliminations			Total
Assets:
At September 30, 2013:	$	4,878,723		$	5,947,558		$	883,750		$	-		$	11,710,031
At December 31, 2012:	$	4,938,954		$	5,183,592		$	8,702		$	-		$	10,131,248
Assets acquired
Three months ended September 30, 2013	$	-		$	54,255		$	-		$	-		$	54,255
Three months ended September 30, 2012	$	-		$	2,283,431		$	-		$	-		$	2,283,431
Nine months ended September 30, 2013	$	67,192		$	261,035		$	-		$	-		$	328,227
Nine months ended September 30, 2012	$	-		$	2,473,799		$	-		$	-		$	2,473,799

SUBSEQUENT_EVENTS_Tables

SUBSEQUENT EVENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Convertible Debt [Table Text Block]	'
	A summary of the use of proceeds received by the Company in the Hillair transaction is as follows:
	Payment in Full of Balance Due on HSR Note (See Notes 8 & 15)	$	300,000.00
	Payment in Full of Balance Due on Accredited Investor Loan (See Notes 9 & 15)		188,850.00
	Legal and Due Diligence Fees Associated with Hillair Transaction	$	98,003.85
	Expansion and Working Capital	$	1,413,146.15
	TOTAL PROCEEDS RECEIVED FROM HILLAIR	$	2,000,000.00

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment, Depreciation Methods	'	'	'straight-line method	'	'	'
Investment Maturity Term	'	'	'90 days or less	'	'	'
Cash and Cash Equivalents, at Carrying Value, Total	$197,020	$197,026	$197,020	$197,026	$67,045	$528,303
Amortization of financing costs	22,802	14,337	51,477	43,011	'	'
Accumulated Amortization, Deferred Finance Costs	127,940	'	127,940	'	76,464	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount	15,628,755	12,806,795	15,217,578	14,498,962	'	'
Amortization Of Intangible Assets	5,000	5,000	15,000	10,000	'	'
Stock Issued During Period, Value, Purchase of Assets	'	'	286,500	'	'	'
Patient lists [Member]	'	'	'	'	'	'
Accumulated Amortization, Deferred Finance Costs	30,000	'	30,000	'	24,391	'
First Choice Medical Group Of Brevard Llc [Member]	'	'	'	'	'	'
Finite-Lived Intangible Assets, Remaining Amortization Period	'	'	'15 years	'	'	'
Patents [Member] | Don Bitter [Member]	'	'	'	'	'	'
Stock Issued During Period, Shares, Purchase of Assets	'	'	636,666	'	'	'
Stock Issued During Period, Value, Purchase of Assets	'	'	$286,500	'	'	'
Maximum [Member]	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'39 years	'	'	'
Minimum [Member]	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life	'	'	'20 years	'	'	'

LIQUIDITY_Details_Textual

LIQUIDITY (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Proceeds from Notes Payable	$152,659	$2,871,058
Subsequent Event [Member] | Secured Convertible Debenture Hillair Capital Investments [Member]	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	'
Ccr Of Melbourne Inc [Member]	'	'
Line of Credit Facility, Amount Outstanding	141,448	'
Ccr Of Melbourne Inc [Member] | Subsequent Event [Member]	'	'
Line of Credit Facility, Amount Outstanding	316,631	'
CT Capital LTD [Member] | Subsequent Event [Member]	'	'
Line of Credit Facility, Amount Outstanding	1,500,000	'
Debt Instrument, Interest Rate During Period	12.00%	'
Debt Instrument, Interest Rate at Period End	6.00%	'
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total	100,000	'
CT Capital LTD [Member] | Subsequent Event [Member] | Convertible Common Stock [Member]	'	'
Conversion of Stock, Amount Converted	1,238,480	'
Hillair Capital Investments L P [Member] | Subsequent Event [Member]	'	'
Proceeds from Issuance of Warrants	2,320,000	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	'
Proceeds from Notes Payable	$2,000,000	'

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT, AND EQUIPMENT (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment, Gross	$10,542,332	$10,222,570
Less: accumulated depreciation	-1,834,133	-1,465,939
Property, plant and equipment, net	8,708,199	8,756,631
Land [Member]	'	'
Property, Plant and Equipment, Gross	1,000,000	1,000,000
Building [Member]	'	'
Property, Plant and Equipment, Gross	3,055,168	3,055,168
Building Improvements [Member]	'	'
Property, Plant and Equipment, Gross	1,758,818	1,691,625
Medical Office Improvement [Member]	'	'
Property, Plant and Equipment, Gross	1,410,028	1,410,028
Automobiles [Member]	'	'
Property, Plant and Equipment, Gross	29,849	29,849
Computer Equipment [Member]	'	'
Property, Plant and Equipment, Gross	188,451	186,549
Medical Equipment [Member]	'	'
Property, Plant and Equipment, Gross	2,204,641	2,039,393
MRI Center [Member]	'	'
Property, Plant and Equipment, Gross	784,999	705,118
Office Equipment [Member]	'	'
Property, Plant and Equipment, Gross	$110,378	$104,840

PROPERTY_PLANT_AND_EQUIPMENT_D1

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Depreciation	$130,885	$73,538	$373,803	$187,420

INVESTMENTS_Details_Textual

INVESTMENTS (Details Textual) (MedTech Diagnostics, LLC [Member])	9 Months Ended
	Sep. 30, 2013
MedTech Diagnostics, LLC [Member]	'
Stock Issued During Period, Shares, Acquisitions	1,000,000
Noncontrolling Interest, Ownership Percentage by Parent	10.00%

LINES_OF_CREDIT_Details_Textua

LINES OF CREDIT (Details Textual) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	1-May-13
			Line of Credit MTI Capital [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Short-term Debt [Member]	Long-term Debt [Member]	Long-term Debt [Member]
				Common Stock [Member]	CT Capital LTD [Member]	Line of Credit MTI Capital [Member]
Short-term Debt, Maximum Amount Outstanding During Period	'	'	'	'	'	'	$1,500,000	'	'
Line of Credit Facility, Interest Rate During Period	'	'	12.00%	'	'	'	12.00%	12.00%	'
Line of Credit Facility, Expiration Date	'	'	'	'	'	'	31-Dec-16	'	'
Line of Credit Facility, Collateral	'	'	'	'	'	'	'The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by Legal Letters of Protection.	'	'
Debt Instrument, Convertible, Terms of Conversion Feature	'	'	'At any time, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into the common stock of the Company at a price equal to $.75 per share.	'	'	'	'At any time, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into the common stock of the Company at a price equal to $.75 per share	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	2,000,000	'	'	'	'	'	2,000,000
Line of Credit Facility, Expiration Period	'	'	'	'	'	'	'	'2 years	'
Long-term Line of Credit, Noncurrent	$502,196	$0	$505,325.91	'	'	$624,000	'	$502,196	'
Debt Instrument, Convertible, Conversion Price	'	'	'	'	'	$0.45	'	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total	'	'	'	'	100,000	'	'	'	'
Debt Instrument, Interest Rate During Period	'	'	'	'	12.00%	'	'	'	'
Debt Instrument, Interest Rate at Period End	'	'	'	'	6.00%	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	'	1,386,667	'	'	'	'	'

LINE_OF_CREDIT_RELATED_PARTY_D

LINE OF CREDIT, RELATED PARTY (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Feb. 01, 2012
Interest Paid	'	'	$703,841	$348,302	'	'
Ccr Of Melbourne Inc [Member]	'	'	'	'	'	'
Line Of Credit Facility, Maximum Borrowing Capacity	500,000	'	500,000	'	'	500,000
Line Of Credit Facility, Expiration Date	'	'	'	'	1-Oct-15	'
Line Of Credit Facility, Interest Rate During Period	'	'	'	'	8.50%	'
Interest Paid	3,883	1,391	7,089	3,331	'	'
Line of Credit Facility, Amount Outstanding	141,448	'	141,448	'	'	'
Ccr Of Melbourne Inc [Member] | Subsequent Event [Member]	'	'	'	'	'	'
Stock Issued During Period, Shares, Conversion of Convertible Securities	'	'	142,483.52	'	'	'
Debt Instrument, Convertible, Conversion Price	$0.45	'	$0.45	'	'	'
Line of Credit Facility, Amount Outstanding	$316,631	'	$316,631	'	'	'

NOTE_PAYABLE_RELATED_PARTY_Det

NOTE PAYABLE, RELATED PARTY (Details Textual) (USD $)	3 Months Ended		9 Months Ended			1 Months Ended	3 Months Ended	9 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Aug. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	17-May-12	Sep. 30, 2013
						Note Payable HS Real LLC [Member]	Note Payable HS Real LLC [Member]	Note Payable HS Real LLC [Member]	Note Payable HS Real LLC [Member]	Note Payable HS Real LLC [Member]
										Subsequent Event [Member]
Notes Payable, Total	$9,857,587	'	$9,857,587	'	$10,100,882	$300,000	'	'	$100,000	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	'	'	'	'	12.00%	'
Increase (Decrease) In Notes Payable, Current	'	'	'	'	'	250,000	'	'	'	'
Proceeds from Issuance of Debt	'	'	'	'	'	50,000	'	'	'	'
Interest Expense, Related Party	3,883	5,912	7,089	7,782	'	'	9,290	27,642	'	'
Repayments Of Notes Payable	'	'	$702,954	$202,002	'	'	'	$300,000	'	$300,000

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Convertible Notes Payable	$58,098	$43,537
Less: current portion	-58,098	-43,537
Convertible Notes Payable, Noncurrent	0	0
Convertible Notes Payable One [Member]	'	'
Convertible Notes Payable	0	43,537
Convertible Notes Payable Two [Member]	'	'
Convertible Notes Payable	$58,098	$0

CONVERTIBLE_NOTES_PAYABLE_Deta1

CONVERTIBLE NOTES PAYABLE (Details Textual) (USD $)

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Feb. 19, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Derivative At Inception Date [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable One [Member]

Convertible Notes Payable Two [Member]

Convertible Notes Payable Two [Member]

Convertible Note Payable Dated August 14 2013 [Member]

Convertible Note Payable Dated August 14 2013 [Member]

Convertible Note Payable Dated August 14 2013 [Member]

Subsequent Event [Member]

Derivative At Inception Date [Member]

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

8.00%

8.00%

8.00%

'

8.00%

8.00%

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

18-Sep-13

16-May-14

'

'

16-May-14

'

Debt Instrument, Unamortized Discount

$106,744

'

$160,543

'

'

'

'

$160,543

$106,744

'

$128,748

$128,748

'

Debt Instrument, Face Amount

'

'

'

'

'

'

103,500

'

'

'

153,500

153,500

'

Proceeds From Convertible Debt

257,000

0

'

'

'

100,000

'

'

'

'

'

151,000

'

Debt Instrument, Prepayments, Discount Rate

'

'

'

'

'

'

'

'

'

'

'

39.00%

'

Embedded Derivative, Fair Value Of Embedded Derivative Liability

'

'

'

97,577

'

'

'

'

'

'

'

'

128,748

Fair Value Assumptions, Expected Dividend Rate

0.00%

'

'

0.00%

'

'

'

'

'

'

'

'

0.00%

Fair Value Assumptions, Expected Volatility Rate

134.94%

'

'

98.67%

'

'

'

'

'

'

'

'

119.96%

Fair Value Assumptions, Weighted Average Volatility Rate

0.04%

'

'

0.17%

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'7 months 13 days

'

'

'9 months

'

'

'

'

'

'

'

'

'9 months

Fair Value Assumptions, Exercise Price

$1.34

'

'

$1.94

'

'

'

'

'

'

'

'

$0.60

Derivative Liability, Current

210,961

'

171,987

'

'

'

'

'

'

'

'

'

'

Embedded Derivative, Loss On Embedded Derivative

82,213

'

'

'

'

'

'

'

'

'

'

'

'

Amortization Of Debt Discount (Premium)

280,125

0

'

'

51,095

97,577

'

'

'

'

22,004

280,125

'

Gain From Change In Fair Value Of Debt Derivative

97,577

'

'

'

'

'

'

'

'

171,987

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

0.12%

Repayments of Convertible Debt

'

'

'

'

'

'

'

'

'

$188,850

'

'

'

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Aug. 12, 2011
Notes Payable	$9,857,587	$10,100,882	'
Less: current portion	-738,349	-690,586	'
Notes payable, long term portion	9,119,238	9,410,296	'
Mortgages [Member]	'	'	'
Notes Payable	7,377,028	7,444,580	7,550,000
Note Payable GE Capital Construction MRI [Member]	'	'	'
Notes Payable	346,226	450,604	'
Note Payable GE Capital 2 [Member]	'	'	'
Notes Payable	114,378	153,340	'
Note Payable, GE Capital (MRI) [Member]	'	'	'
Notes Payable	1,647,155	1,806,932	'
Note Payable GE Capital X Ray [Member]	'	'	'
Notes Payable	193,904	213,126	'
Note Payable GE Arm [Member]	'	'	'
Notes Payable	119,999	0	'
Note Payable Auto [Member]	'	'	'
Notes Payable	23,560	27,300	'
Note Payable Dr Richard Newman [Member]	'	'	'
Notes Payable	0	5,000	'
Capital lease, Equipment [Member]	'	'	'
Notes Payable	$35,337	$0	'

NOTES_PAYABLE_Details_1

NOTES PAYABLE (Details 1) (USD $)	Sep. 30, 2013
Long-term Debt, Fiscal Year Maturity [Abstract]	'
Three months ended December 31, 2013	$413,780
Year ended December 31, 2014	740,543
Year ended December 31, 2015	719,433
Year ended December 31, 2016 and after	7,983,831
Total	$9,857,587

NOTES_PAYABLE_Details_Textual

NOTES PAYABLE (Details Textual) (USD $)

9 Months Ended

12 Months Ended

12 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2012

Mar. 08, 2013

Aug. 22, 2012

Dec. 31, 2012

Mar. 08, 2013

Sep. 27, 2012

Sep. 30, 2013

Jun. 30, 2013

Aug. 31, 2011

Sep. 30, 2013

Dec. 31, 2012

Aug. 12, 2011

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 24, 2012

Sep. 30, 2013

Dec. 31, 2012

Aug. 31, 2012

17-May-12

Sep. 30, 2013

Dec. 31, 2012

21-May-12

Sep. 30, 2013

Dec. 31, 2012

21-May-13

X Ray Equipment [Member]

X Ray Equipment [Member]

X Ray Equipment [Member]

MRI Equipment [Member]

MRI Equipment [Member]

MRI Equipment [Member]

C-Arm Equipment [Member]

Equipment Capital Lease [Member]

Mortgages [Member]

Mortgages [Member]

Mortgages [Member]

Mortgages [Member]

Note Payable GE Capital [Member]

Note Payable GE Capital Construction MRI [Member]

Note Payable GE Capital Construction MRI [Member]

Note Payable GE Capital Construction MRI [Member]

Note Payable GE Capital 2 [Member]

Note Payable GE Capital 2 [Member]

Note Payable GE Capital 2 [Member]

Note Payable HS Real LLC [Member]

Note Payable HS Real LLC [Member]

Note Payable Dr Richard Newman [Member]

Note Payable Dr Richard Newman [Member]

Note Payable Auto [Member]

Note Payable Auto [Member]

Note Payable Auto [Member]

GE Healthcare Financial Services [Member]

Equipment Finance Lease [Member]

Notes Payable

$9,857,587

'

$10,100,882

'

'

'

'

'

'

'

'

'

$7,377,028

$7,444,580

$7,550,000

'

'

$346,226

$450,604

'

$114,378

$153,340

$300,000

$100,000

$0

$5,000

'

$23,560

$27,300

$2,400,000

Debt Instrument, Interest Rate During Period

'

'

'

'

'

'

'

'

'

'

'

6.10%

'

'

'

'

7.38%

'

'

7.38%

'

'

'

'

'

'

6.99%

'

'

'

Debt Instrument, Periodic Payment

'

'

'

'

'

'

'

'

'

'

956.45

45,752.61

'

'

'

'

'

'

'

'

'

'

'

'

'

'

593

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

'

1-Jun-17

16-Sep-16

'

'

'

'

'

'

'

'

'

'

'

'

1-Jan-13

'

30-Jun-17

'

'

'

Interest and Debt Expense, Total

'

'

'

'

'

'

'

'

'

'

'

286,723

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital Lease Obligations

'

'

'

'

'

212,389

'

'

1,771,390

117,322

'

'

'

'

'

2,288,679

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Construction Loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

450,000

'

'

150,000

'

'

'

'

'

'

'

'

'

'

Non Interest Bearing Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

Construction Loan Term

'

'

'

'60 months

'

'

'60 months

'

'

'63 months

'48

'

'

'

'

'

'35 monthly

'

'

'35 monthly

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

7.94%

'

'

7.94%

7.39%

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

'

'

Capital Lease Obligations Due In First 3 Months

'

'

'

'

1,384

0

'

11,779

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital Lease Obligations Due For Remaining Months

'

'

'

'

4,575

4,300

'

38,152

38,152

2,388

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,000

'

'

'

'

'

Proceeds From Notes Payable

$152,659

$2,871,058

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$29,850

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

'

'

'

'

'

'

14.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Aug. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

17-May-12

Sep. 30, 2013

Sep. 30, 2013

Feb. 01, 2012

Sep. 30, 2013

Patents [Member]

Note Payable HS Real LLC [Member]

Note Payable HS Real LLC [Member]

Note Payable HS Real LLC [Member]

Note Payable HS Real LLC [Member]

Note Payable HS Real LLC [Member]

Ccr Of Melbourne Inc [Member]

Ccr Of Melbourne Inc [Member]

Ccr Of Melbourne Inc [Member]

Don Bitter [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Line Of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

$500,000

$500,000

'

Line Of Credit Facility, Amount Outstanding

'

'

'

'

'

'

'

'

'

'

'

141,448

'

316,631

Interest Expense, Related Party

3,883

5,912

7,089

7,782

'

'

'

9,290

27,642

'

'

'

'

'

Notes Payable, Total

9,857,587

'

9,857,587

'

10,100,882

'

300,000

'

'

100,000

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

Increase (Decrease) In Notes Payable, Current

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

Proceeds from Issuance of Debt

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Purchase of Assets

'

'

'

'

'

636,666

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Purchase of Assets

'

'

286,500

'

'

286,500

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

142,483.52

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.45

Repayments Of Notes Payable

'

'

$702,954

$202,002

'

'

'

'

$300,000

'

$300,000

'

'

'

CAPITAL_STOCK_Details

CAPITAL STOCK (Details)	9 Months Ended
	Sep. 30, 2013
Stock Issued During Period, Shares, Issued for Services	921,666
Board of Directors [Member]	'
Stock Issued During Period, Shares, Issued for Services	105,000
Officers and Employees [Member]	'
Stock Issued During Period, Shares, Issued for Services	756,666	[1]
Professional Service Providers [Member]	'
Stock Issued During Period, Shares, Issued for Services	60,000
[1]	As detailed in Note 11 - Related Party Transactions above, shares issued to Officers and Employees includes 636,666 shares of common stock issued to Donald Bittar, the Company's CFO, to acquire a patent.

CAPITAL_STOCK_Details_Textual

CAPITAL STOCK (Details Textual)	9 Months Ended
	Sep. 30, 2013
Donald Bittar [Member] | Patent [Member]	'
Stock Issued During Period, Shares, Purchase of Assets	636,666
Common Stock [Member]	'
Stock Issued During Period, Shares, Purchase of Assets	636,666

STOCK_OPTIONS_AND_WARRANTS_Det

STOCK OPTIONS AND WARRANTS (Details) (Non Employees [Member], Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Non Employees [Member] | Warrant [Member]	'	'	'
Warrants Outstanding, Prices (in dollars per share)	$3.60	'	'
Warrants Outstanding	1,875,000	1,875,000	1,875,000
Warrants Outstanding, Expiration Date	31-Dec-16	'	'
Warrants Outstanding, Weighted Price (in dollars per share)	$3.60	$3.60	$3.60
Warrants Exercisable	1,875,000	'	'
Warrants Exercisable, Weighted Price (in dollars per share)	$3.60	'	'

STOCK_OPTIONS_AND_WARRANTS_Det1

STOCK OPTIONS AND WARRANTS (Details 1) (Non Employees [Member], Warrant [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Non Employees [Member] | Warrant [Member]	'	'
Number of Shares, Outstanding	1,875,000	1,875,000
Number of Shares, Granted	0	0
Number of Shares, Exercised	0	0
Number of Shares, Expired	0	0
Number of Shares, Outstanding	1,875,000	1,875,000
Weighted Average Price Per Share, Outstanding	$3.60	$3.60
Weighted Average Price Per Share, Granted	$0	$0
Weighted Average Price Per Share, Exercised	$0	$0
Weighted Average Price Per Share, Expired	$0	$0
Weighted Average Price Per Share, Outstanding	$3.60	$3.60

SEGMENT_REPORTING_Details

SEGMENT REPORTING (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Revenue:	'	'	'	'	'
Net Patient Service Revenue	$1,395,610	$798,077	$3,739,435	$1,707,694	'
Rental revenue	259,120	270,547	786,546	883,179	'
Total Revenue	1,654,730	1,068,624	4,525,981	2,590,873	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	735,888	470,334	2,000,436	1,029,692	'
Other operating expenses	353,034	282,813	965,923	589,442	'
General and administrative	298,566	376,143	898,911	987,861	'
Depreciation and amortization	132,843	73,518	382,268	187,420	'
Total operating expenses	1,511,866	1,202,808	4,239,072	2,794,415	'
Net income (loss) from operations:	142,864	-134,184	278,443	-203,542	'
Interest expense	-302,590	-135,652	-983,966	-372,515	'
Amortization of financing costs	-22,802	-14,337	-51,477	-43,011	'
Gain on change in derivative liability	-1,631	0	187,351	0	'
Other income (expense)	750	750	2,313	2,250	'
Net Income (loss):	-183,409	-283,423	-558,870	-616,818	'
Income taxes	0	0	0	-23,103	'
Net income (loss)	-183,409	-283,423	-558,870	-593,715	'
ASSETS	'	'	'	'	'
Assets	11,710,031	'	11,710,031	'	10,131,248
Assets acquired	'	'	'	'	'
Assets acquired	54,255	2,283,431	319,762	2,473,799	'
Marina Towers [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Net Patient Service Revenue	0	0	0	0	'
Rental revenue	365,839	364,081	1,104,405	1,094,466	'
Total Revenue	365,839	364,081	1,104,405	1,094,466	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	3,000	3,000	9,000	9,000	'
Other operating expenses	95,689	111,449	289,765	289,937	'
General and administrative	21,791	10,019	61,132	52,983	'
Depreciation and amortization	41,571	40,365	123,313	121,095	'
Total operating expenses	162,051	164,833	483,210	473,015	'
Net income (loss) from operations:	203,788	199,248	621,195	621,451	'
Interest expense	-115,241	-116,576	-347,406	-348,227	'
Amortization of financing costs	-14,337	-14,337	-43,011	-43,011	'
Gain on change in derivative liability	0	'	0	'	'
Other income (expense)	750	750	2,313	2,250	'
Net Income (loss):	74,960	69,085	233,091	232,463	'
Income taxes	0	0	0	-8,707	'
Net income (loss)	74,960	69,085	233,091	223,756	'
ASSETS	'	'	'	'	'
Assets	4,878,723	'	4,878,723	'	4,938,954
Assets acquired	'	'	'	'	'
Assets acquired	0	0	67,192	0	'
Fcid Medical [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Net Patient Service Revenue	1,395,610	798,077	3,739,435	1,707,694	'
Rental revenue	0	0	0	0	'
Total Revenue	1,395,610	798,077	3,739,435	1,707,694	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	574,487	406,055	1,583,238	795,375	'
Other operating expenses	357,696	319,039	994,017	510,792	'
General and administrative	140,039	173,525	447,024	408,162	'
Depreciation and amortization	91,272	33,153	258,955	66,325	'
Total operating expenses	1,163,494	931,772	3,283,234	1,780,654	'
Net income (loss) from operations:	232,116	-133,695	456,201	-72,960	'
Interest expense	-78,039	-16,989	-208,773	-18,858	'
Amortization of financing costs	0	0	0	0	'
Gain on change in derivative liability	0	'	0	'	'
Other income (expense)	0	0	0	0	'
Net Income (loss):	154,077	-150,684	247,428	-91,818	'
Income taxes	0	0	0	3,439	'
Net income (loss)	154,077	-150,684	247,428	-88,379	'
ASSETS	'	'	'	'	'
Assets	5,947,558	'	5,947,558	'	5,183,592
Assets acquired	'	'	'	'	'
Assets acquired	54,255	2,283,431	261,035	2,473,799	'
Corporate Segment [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Net Patient Service Revenue	0	0	0	0	'
Rental revenue	0	0	0	0	'
Total Revenue	0	0	0	0	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	158,401	61,279	408,198	225,317	'
Other operating expenses	0	'	0	'	'
General and administrative	136,736	138,458	390,755	526,716	'
Depreciation and amortization	0	0	0	0	'
Total operating expenses	295,137	199,737	798,953	752,033	'
Net income (loss) from operations:	-295,137	-199,737	-798,953	-752,033	'
Interest expense	-109,310	-2,087	-427,787	-5,430	'
Amortization of financing costs	0	0	0	0	'
Gain on change in derivative liability	-1,631	'	187,351	'	'
Other income (expense)	0	0	0	0	'
Net Income (loss):	-406,078	-201,824	-1,039,389	-757,463	'
Income taxes	0	0	0	28,371	'
Net income (loss)	-406,078	-201,824	-1,039,389	-729,092	'
ASSETS	'	'	'	'	'
Assets	883,750	'	883,750	'	8,702
Assets acquired	'	'	'	'	'
Assets acquired	0	0	0	0	'
Intersegment Eliminations [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Net Patient Service Revenue	0	0	0	0	'
Rental revenue	-106,719	-93,534	-317,859	-211,287	'
Total Revenue	-106,719	-93,534	-317,859	-211,287	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	0	'	0	'	'
Other operating expenses	-100,351	-147,675	-317,859	-211,287	'
General and administrative	0	54,141	0	'	'
Depreciation and amortization	0	0	0	0	'
Total operating expenses	-100,351	-93,534	-317,859	-211,287	'
Net income (loss) from operations:	-6,368	0	0	0	'
Interest expense	0	0	0	0	'
Amortization of financing costs	0	0	0	0	'
Gain on change in derivative liability	0	'	0	'	'
Other income (expense)	0	0	0	0	'
Net Income (loss):	-6,368	0	0	0	'
Income taxes	0	0	0	0	'
Net income (loss)	-6,368	0	0	0	'
ASSETS	'	'	'	'	'
Assets	0	'	0	'	0
Assets acquired	'	'	'	'	'
Assets acquired	$0	$0	$0	$0	'

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent Event [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Hillair Capital Investments L P [Member]	'
Legal and Due Diligence Fees Associated with Hillair Transaction	$98,003.85
Expansion and Working Capital	1,413,146.15
TOTAL PROCEEDS RECEIVED FROM HILLAIR	2,000,000
Convertible Notes Payable Two [Member]	'
Payment in Full of Balance Due on Accredited Investor Loan (See Notes 9 & 15)	188,850
Note Payable Hs Real Llc [Member]	'
Payment in Full of Balance Due on HSR Note (See Notes 8 & 15)	$300,000

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)

9 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Aug. 31, 2012

Sep. 30, 2013

17-May-12

Dec. 31, 2012

Sep. 30, 2013

Feb. 01, 2012

Sep. 30, 2013

Sep. 30, 2013

Feb. 19, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jun. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Note Payable Hs Real Llc [Member]

Note Payable Hs Real Llc [Member]

Note Payable Hs Real Llc [Member]

CCR Of Melbourne Inc [Member]

CCR Of Melbourne Inc [Member]

CCR Of Melbourne Inc [Member]

Line of Credit MTI Capital [Member]

Hillair Capital Investments L P [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable Two [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Note Payable Hs Real Llc [Member]

Secured Convertible Debenture Hillair Capital Investments [Member]

CCR Of Melbourne Inc [Member]

CT Capital LTD [Member]

Line of Credit MTI Capital [Member]

Hanover Elite [Member]

Hanover Elite [Member]

Hanover Elite [Member]

Hanover Elite [Member]

Hanover Elite [Member]

Hillair Capital Investments L P [Member]

Hillair Capital Investments L P [Member]

Convertible Notes Payable Two [Member]

Shares Issue One [Member]

Shares Issue Two [Member]

Shares Issue Three [Member]

Shares Issue Four [Member]

Minimum Convertible Price [Member]

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

12.00%

'

'

'

'

'

8.00%

8.00%

'

8.00%

'

'

'

'

'

'

'

'

8.00%

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

$103,500

'

'

$2,000,000

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

$0.45

'

$0.45

'

'

'

'

'

$1

$1

'

Debt Instrument, Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'In conjunction with the debenture, a warrant was issued to purchase up to a number of shares of common stock equal to 100% of the principle amount of the debenture, divided by $1.00. The exercise price is $1.35, subject to any further adjustments in the debenture.

'

'

'

'

'

'

'

'

'

'

'

Subsequent Event, Date

'

'

'

'

'

'

'

'

'

'

'

'

'

8-Nov-13

8-Nov-13

8-Nov-13

8-Nov-13

8-Nov-13

'

'

'

'

'

'

'

8-Nov-13

Notes Payable, Total

9,857,587

'

10,100,882

300,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Notes Payable, Current

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Debt

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments Of Notes Payable

702,954

202,002

'

'

300,000

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

500,000

500,000

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

2,320,000

'

'

Line of Credit Facility, Interest Rate During Period

'

'

'

'

'

'

8.50%

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Expiration Date

'

'

'

'

'

'

1-Oct-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Amount Outstanding

'

'

'

'

'

'

'

141,448

'

'

'

'

'

'

'

316,631

1,500,000

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

142,483.52

'

1,386,667

'

'

'

'

'

'

'

'

Long-term Line of Credit, Noncurrent

502,196

'

0

'

'

'

'

'

'

505,325.91

'

'

'

'

'

'

'

624,000

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Terms of Conversion Feature

'

'

'

'

'

'

'

'

'

'At any time, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into the common stock of the Company at a price equal to $.75 per share.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of Convertible Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

188,850

Gain From Change In Fair Value Of Debt Derivative

97,577

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

171,987

Stock Issued During Period, Shares, Other

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

Loan Modification Agreement Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Under the loan modification agreement, the annual rate of interest was reduced from 12% per annum to 6% per annum and will remain at 6% until November 1, 2015. All other terms under the June 18, 2013 Loan and Security Agreement will remain the same.

'

'

'

'

'

'

'

'

'

Payments under service agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000

'

'

'

'

'

'

'

Shares issuable under service agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

Debt Instrument, Issuance Date

'

'

'

'

'

'

'

'

'

'

8-Nov-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,320,000

'

'

Proceeds from Notes Payable

152,659

2,871,058

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

Debt Instrument, Frequency of Periodic Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'payable quarterly on August 1, November 1, February 1, and May 1, beginning on August 1, 2014

'

'

Debt Instrument, Repurchase Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$580,000

'

'

Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

120.00%

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.35

'

'

Shares Under Service Agreements Earned And Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,500

37,500

37,500

187,500

'

'

'